{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-018812","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2024-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.096167+00:00","generated_at":"2026-06-06T15:04:47.729233+00:00","sec_items":["1.01","5.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"AVROBIO to merge with Tectonic in all-stock deal; $130.7M private financing; combined company targets GPCRs","bullets":["Pre-merger AVRO holders expected to own ~22.3%; Tectonic holders ~40.2%; financing investors ~37.5% of combined firm.","Concurrent $130.7M private placement from new and existing life sciences investors; combined cash ~$165M at close, runway into mid-2027.","Combined company to advance Tectonic's lead asset TX45 (Fc-relaxin fusion protein) through clinical catalysts.","AVRO stockholders to receive CVRs for contingent payments from future monetization of AVRO's legacy gene therapy assets.","Support agreements from ~88% of Tectonic voting power and ~10.8% of AVRO shares; 180-day lock-up for insiders."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-018812","json":"https://secwatch.observer/filing/0001193125-24-018812.json","markdown":"https://secwatch.observer/filing/0001193125-24-018812.md","text":"https://secwatch.observer/filing/0001193125-24-018812.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312524018812/0001193125-24-018812-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312524018812/d221662d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:04:47.729233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e8d4cdfc61ea42e841e3b1eec14dd30cd10cd5d","claim":"Tectonic Therapeutic, Inc. entered into Agreement and Plan of Merger and Reorganization with AVROBIO, Inc. and Alpine Merger Subsidiary, Inc. (effective 2024-01-30).","evidence_excerpt":"On January 30, 2024, AVROBIO, Inc., a Delaware corporation (“AVRO”), Alpine Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of AVRO (“Merger Sub”), and Tectonic Therapeutic, Inc., a Delaware corporation (“Tectonic”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681087/000119312524018812/0001193125-24-018812-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"AVROBIO, Inc. and Alpine Merger Subsidiary, Inc."},{"label":"Effective","value":"2024-01-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}